SNDX - シンダックス・ファ―マシュ―ティカルズ (Syndax Pharmaceuticals Inc.) シンダックス・ファ―マシュ―ティカルズ

 SNDXのチャート


 SNDXの企業情報

symbol SNDx
会社名 Syndax Pharmaceuticals Inc (シンダックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 シンダックス・ファーマシューティカルズ(Syndax Pharmaceuticals Inc)は癌の適応症の併用療法のパイプラインを開発することに焦点を当てた臨床段階のバイオ医薬品会社である。製品候補であるエンジノスタット(entinostat)は、フェーズⅡb臨床試験ENCORE 301からの肯定的な結果に続いて、FDAによるブレークスルー療法指定を与えられ、進行ホルモン受容体陽性乳癌の第III相臨床試験で評価される。癌細胞と免疫調節細胞に直接作用するentinostatと、抗CSF-1Rモノクローナル抗体SNDX-6352が、免疫療法に感受性を示す腫瘍に対する身体の免疫応答を増強させている。entinostatは、非小細胞肺癌および黒色腫のためのMerck_Co. Inc.、TNBCのGenentech Inc.および卵巣癌のためのPfizer Inc.およびMerck KGaA Darmstadt Germanyによって、フェーズIb / II臨床試験における併用療法として評価されている。   シンダックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、腫瘍に対する免疫治療の発見・商業化に従事する。経口薬であるエンチノスタットはがん細胞と免疫調整細胞に影響を与え、体の免疫機能を強化させる。肺がん、黒色腫、卵巣がん、乳がんに対する治療に使用される。本社はマサチュ―セッツ州ウォルトハム。   Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
本社所在地 35 Gatehouse Drive Building D Floor 3 Waltham MA 02451 USA
代表者氏名 Dennis G. Podlesak Dennis G. Podlesak
代表者役職名 Independent Chairman of the Board
電話番号 +1 781-419-1400
設立年月日 38626
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 45人
url www.syndax.com
nasdaq_url https://www.nasdaq.com/symbol/sndx
adr_tso
EBITDA EBITDA(百万ドル) -73.41700
終値(lastsale) 7.37
時価総額(marketcap) 172126445.81
時価総額 時価総額(百万ドル) 170.25800
売上高 売上高(百万ドル) 2.25600
企業価値(EV) 企業価値(EV)(百万ドル) 70.46800
当期純利益 当期純利益(百万ドル) -71.97700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Syndax Pharmaceuticals Inc revenues increased 24% to $758K. Net loss increased 42% to $37.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 56% to $29.2M (expense) General and administrative increase of 20% to $7.2M (expense).

 SNDXのテクニカル分析


 SNDXのニュース

   Incyte and Syndax to jointly develop and commercialise axatilimab  2021/09/28 14:12:17 Pharmaceutical Business Review
Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases. Axatilimab is an The post Incyte and Syndax to jointly develop and commercialise axatilimab appeared first on Pharmaceutical Business review .
   Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate  2021/09/27 13:23:11 Benzinga
Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) and Incyte Corporation (NASDAQ: INCY ) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax''s axatilimab. Related Content: Syndax Pharma Receives FDA Orphan Drug Designation For Axatilimab For Treatment Of Chronic Graft vs. Host Disease Syndax and Incyte seek to develop axatilimab for chronic graft-versus-host Full story available on Benzinga.com
   Syndax Partners With Incyte To Develop, Commercialize Axatilimab  2021/09/27 10:40:00 FinanzNachrichten
WASHINGTON (dpa-AFX) - Syndax Pharmaceuticals, Inc. (SNDX) and Incyte (INCY) have entered into a worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax''s ant
   Syndax Partners With Incyte To Develop, Commercialize Axatilimab - Quick Facts  2021/09/27 10:19:44 Business Insider Markets
(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX) and Incyte (INCY) have entered into a worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax''s anti-CSF-1R monoclonal antibody. Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:
   Syndax Pharmaceuticals Inc (SNDX) President and COO Michael A Metzger Sold $702,741 of Shares  2021/09/23 00:15:01 GuruFocus
Related Stocks: SNDX ,
   Head to Head Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Iterum Therapeutics (NASDAQ:ITRM)  2021/03/13 00:27:10 Modern Readers
Syndax Pharmaceuticals (NASDAQ:SNDX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings. Volatility & Risk Syndax Pharmaceuticals has a beta of 1.8, suggesting that its share price […]
   Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates  2021/03/09 08:38:36 Smarter Analyst
Syndax Pharmaceuticals reported a better-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. Shares of the clinical-stage biopharmaceutical company dropped … The post Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates appeared first on Smarter Analyst .
   Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $29.00 by Analysts at Barclays  2020/11/20 13:08:52 Transcript Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lifted by Barclays from $23.00 to $29.00 in a report published on Thursday, The Fly reports. Barclays currently has an overweight rating on the stock. Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a […]
   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.7%  2020/10/23 17:48:41 US Banking News
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) rose 5.7% during mid-day trading on Friday . The company traded as high as $16.18 and last traded at $16.01. Approximately 590,192 shares traded hands during mid-day trading, an increase of 20% from the average daily volume of 491,370 shares. The stock had previously closed at $15.14. SNDX has been the […]
   Head to Head Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Iterum Therapeutics (NASDAQ:ITRM)  2021/03/13 00:27:10 Modern Readers
Syndax Pharmaceuticals (NASDAQ:SNDX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings. Volatility & Risk Syndax Pharmaceuticals has a beta of 1.8, suggesting that its share price […]
   Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates  2021/03/09 08:38:36 Smarter Analyst
Syndax Pharmaceuticals reported a better-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. Shares of the clinical-stage biopharmaceutical company dropped … The post Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates appeared first on Smarter Analyst .
   Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $29.00 by Analysts at Barclays  2020/11/20 13:08:52 Transcript Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lifted by Barclays from $23.00 to $29.00 in a report published on Thursday, The Fly reports. Barclays currently has an overweight rating on the stock. Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a […]
   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.7%  2020/10/23 17:48:41 US Banking News
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) rose 5.7% during mid-day trading on Friday . The company traded as high as $16.18 and last traded at $16.01. Approximately 590,192 shares traded hands during mid-day trading, an increase of 20% from the average daily volume of 491,370 shares. The stock had previously closed at $15.14. SNDX has been the […]

 関連キーワード  (医薬品 米国株 シンダックス・ファ―マシュ―ティカルズ SNDX Syndax Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)